Conference Proceedings
CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines.
Joshua Hoenisch, Hannah Kim, Amy Dawson, Nicole Lam, Dane A Cheasley, Kylie Gorringe, Ian Campbell, David G Huntsman, Gabriel DiMattia, Martin Kobel, Marta Llaurado Fernandez, Mark S Carey
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2020
Abstract
Abstract Background: Low-grade serous ovarian cancer (LGSC) is a rare tumor type that requires effective therapies. CDKN2A/B (p16/p15) loss and oncogenic mutations in MAPK genes are common genetic aberrations found in these tumors. We aimed to evaluate CDK4/6 inhibitor (palbociclib) activity, with and without MEK inhibitor (trametinib) treatment, in LGSC cell lines. Methods: Nine LGSC cell lines (from advanced/recurrent cases) were used to evaluate the effects of palbociclib treatment, with and without trametinib, on cell proliferation (Incucyte) and viability (MTS). Cell cycle gene and protein expression status (p16, CDK4, CDK6, Rb, p-Rb, CCDN1 and E2F) were ch..
View full abstract